Tag: Prescription Drugs

Statement of Commissioner Rebecca Kelly Slaughter Regarding the Policy Statement of the Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Prices (155.17 KB)

Statement of Commissioner Rebecca Kelly Slaughter Regarding the Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products

Date

June 16, 2022

Rebecca Kelly Slaughter, Commissioner

Matter Number

P221201

FTC to Ramp Up Enforcement Against Any Illegal Rebate Schemes, Bribes to Prescription Drug Middleman That Block Cheaper Drugs

Date

June 16, 2022

The Federal Trade Commission announced that it will ramp up enforcement against any illegal bribes and rebate schemes that block patients’ access to competing lower-cost drugs. The enforcement policy...

Policy Statements

Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower Cost Drug Products

Date

June 16, 2022

Matter Number

P221201

Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products (258.92 KB)

Statement of Commissioner Christine S. Wilson Regarding the Commission Policy Statement on Rebates and Fees in Exchange for Excluding Lower Drug Cost Products (180.17 KB)

Statement of Commissioner Christine S. Wilson Regarding the FTC Policy Statement on Rebates and Fees in Exchange for Excluding Lower Cost Drug Products

Date

June 16, 2022

Christine S. Wilson, Commissioner

Public Statement

Oral Remarks of Christine S. Wilson at Open Commission Meeting on June 16, 2022

Date

June 16, 2022

Oral Remarks of Christine S. Wilson at Open Commission Meeting on June 16, 2022 (245.29 KB)

Statement of Commissioner Alvaro M. Bedoya Regarding the Commission's Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products

Date

June 16, 2022

Alvaro Bedoya, Commissioner

Matter Number

P221201

Statement of Commissioner Alvaro M. Bedoya Regarding the Commission's Rebate Policy Statement (148.98 KB)

Public Statement

Keynote Remarks of Commissioner Rebecca Kelly Slaughter at the FTC/DOJ Pharmaceutical Task Force Workshop

Date

June 14, 2022

Keynote Remarks of Commissioner Rebecca Kelly Slaughter at the FTC/DOJ Pharmaceutical Task Force Workshop (186.47 KB)

FTC and Justice Department to Hold Two-Day Virtual Public Workshop Starting Tomorrow that Re-examines Antitrust Enforcement in the Pharmaceutical Industry

Date

June 13, 2022

The Federal Trade Commission and the U.S. Department of Justice (DOJ) will host a two-day workshop starting tomorrow, that explores new approaches to enforcing the antitrust laws in the pharmaceutical...

Statement of Chair Lina M. Khan Regarding 6(b) Study of Pharmacy Benefit Managers

Date

June 7, 2022

Lina M. Khan, Chair

Statement of Chair Lina M. Khan Regarding 6(b) Study of Pharmacy Benefit Managers (104.88 KB)

Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding 6(b) Study of Pharmacy Benefit Managers

Date

June 7, 2022

Noah Joshua Phillips, Former Commissioner;

Christine S. Wilson, Commissioner

Matter Number

P221200

Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson (182.82 KB)

FTC Launches Inquiry Into Prescription Drug Middlemen Industry

Date

June 7, 2022

The Federal Trade Commission announced today that it will launch an inquiry into the prescription drug middleman industry, requiring the six largest pharmacy benefit managers to provide information...

FTC and Justice Department to Hold Two-Day Virtual Public Workshop Examining Antitrust Enforcement in the Pharmaceutical Industry

Date

May 31, 2022

The Federal Trade Commission and the U.S. Department of Justice (DOJ) will host a two-day workshop to explore new approaches to enforcing the antitrust laws in the pharmaceutical industry. The...

Federal Register Notice

Hikma Pharmaceuticals PLC/Custopharm, Inc.; Analysis of Agreement Containing Consent Orders To Aid Public Comment

Date

May 4, 2022

Public Statement

Remarks of Chair Lina M. Khan Regarding the 6(b) Study on Pharmacy Benefit Managers

Date

February 17, 2022

Matter Number

P221002

Text of Statement (195.96 KB)

Statement of Chair Lina M. Khan on the Ruling by Judge Denise L. Cote Regarding Federal Trade Commission et al v. Vyera Pharmaceuticals, LLC et al Regarding

Date

January 14, 2022

Lina M. Khan, Chair

Statement of Chair Lina M. Khan on the Ruling by Judge Denise L. Cote (183.61 KB)